Opus Genetics (IRD)

• Market cap: $178M
• 1 day: 12.66%
• 5 days: 5.31%
• 1 month: 21.13%
• 3 months: 21.7%
• 6 months: 132.43%
• Year to date: 21.7%
• 1 year: 113.22%
• 5 years: -75.43%
• 10 years: -98.51%
• Sector: Healthcare
• Industry: Biotechnology

About: Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.

Employees: 18